期刊文献+

恶性胸膜间皮瘤的靶向治疗研究进展 被引量:4

Latest research progress at targeted therapy for malignant pleural mesothelioma
原文传递
导出
摘要 恶性胸膜间皮瘤(MPM)是临床上恶性程度高、早期诊断困难、预后极差的肺部疾病,在我国发病率有逐渐上升的趋势。大多数患者发现时已处于晚期,无手术切除指征,而且对放化疗不敏感。靶向治疗是目前肿瘤的研究热点,在MPM领域也取得了进展,有望改善MPM患者的预后。作者对靶向治疗研究的进展进行了综述。 Malignant pleural mesothelioma(MPM) is a lung disease difficult to diagnose in early stage with the highest level of clinical malignancy and extremely poor prognosis. Its incidence tends to rise gradually in China. Most diagnosed patients are already in the advanced stage with no indications for surgical resection and are insensitive to radiotherapy and chemotherapy.Targeted therapy is now the hot spot of cancer research. New progress has been achieved in the MPM field and shows promise of improving the outcomes of MPM patients. The authors review the research progress of targeted therapy.
出处 《职业与健康》 CAS 2016年第10期1437-1440,共4页 Occupation and Health
基金 中山市科技计划项目(2014A1FC008)
关键词 恶性胸膜间皮瘤 靶向治疗 Malignant pleural mesothelioma(MPM) Targeted therapy
  • 相关文献

参考文献25

  • 1YANG H,TESTA JR,CARBONE M. Mesothelioma epidemiology,car-cinogenesis, and Pathogenesis [ J ]. Curr Treat Options Oncol 2008,9 (2-3) : 147-157.
  • 2CARBONE M,KRATZKE RA,TESTA JR. The pathogenesis of mesothe- lioma [J].Semin Oncol,2002,29( 1 ) :2-17.
  • 3OHANSSON L, LINDEN CJ. Aspects of histopathologic subtype as a prognostic factor in 85 pleural mesotheliomas [ J ]. Chest, 1996,109 ( 1 ) : 109-114.
  • 4ROBINSON BW, MUSK AW, LAKE RA. Malignant mesothelioma[J]. Lancet, 2005, 366(9483 ) : 397-408.
  • 5GRONDIN SC,SUGARBAKER DJ. Malignant mesothelioma of the pleural space[J]. Oncology, 1999,13(7) :919-926.
  • 6VOGELZANG NJ, RUSTHOVEN JJ,SYMANOWSKI J,et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma [J].J Clin Oncol, 2003,21 (14) : 2636-2644.
  • 7AOEK,HIRAKI A,TANAKA T,et al. Expression of vascular endothe- lial growth factor in malignant mesothelioma [J].Anticancer Res, 2006,26(6C) :4833-4836.
  • 8YASUMISTU A,TABATA C,TABATA R,et al. Clinical significance of serum vascular endothelial growth factor in malignant pleural mesothe- lioma[J].J Thorac Oncol, 2011,5 (4) : 479-483.
  • 9ZALCMAN G,MAZIERES J,MARGERY J,et al. Bevacizumab 15mg/ kg plus cisplatin-pemetrexed (CP) triplet versus CP doublet in Malig- nant Pleural Mesothelioma (MPM): Results of the IFCT-GFPC-0701 MAPS randomized phase 3 trial [J].J Clin Oncol, 2015,33 (Suppl) : abstr 7500.
  • 10ENOMOTOY,KASAIT,TAKEDAM, etalEpidermalgrowthfactor receptor mutations in malignant pleural and peritoneal mesothelioma [J]. J Clin Pathol,2012, 65(6) :522-527.

同被引文献25

引证文献4

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部